Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hjerrild, Kathryn A ^a   Jin, Jing ^a   Wright, Katherine E ^b   Brown, Rebecca E ^a   Marshall, Jennifer M ^a   Labbé, Geneviève M ^a   Silk, Sarah E ^a   Cherry, Catherine J ^a   Clemmensen, Stine B ^c   Jørgensen, Thomas ^c   Illingworth, Joseph J ^a   Alanine, Daniel G W ^a   Milne, Kathryn H ^a   Ashfield, Rebecca ^a   De Jongh, Willem A ^c   Douglas, Alexander D ^a   Higgins, Matthew K ^b   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CD147 ANTIGEN; IMMUNOGLOBULIN G; MALARIA VACCINE; MONOCLONAL ANTIBODY; RH5 PROTEIN, PLASMODIUM FALCIPARUM;

ANIMAL; CELL LINE; DROSOPHILA MELANOGASTER; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIBODIES, MONOCLONAL; BASIGIN; CARRIER PROTEINS; CELL LINE; DROSOPHILA MELANOGASTER; IMMUNOGLOBULIN G; MALARIA VACCINES; MUTATION; PLASMODIUM FALCIPARUM;

EID: 84979587974     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30357     Document Type: Article

References (60)

1. Rts, S. C. T. P. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31-45 (2015).
2. Goodman, A. L. & Draper, S. J. Blood-stage malaria vaccines-recent progress and future challenges. Ann Trop Med Parasitol 104, 189-211 (2010).
3. Nikolaeva, D., Draper, S. J. & Biswas, S. Toward the development of effective transmission-blocking vaccines for malaria. Expert. Rev. Vaccines, 1-28 (2015).
4. Takala, S. L. et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci. Transl. Med. 1, 2ra5 (2009).
5. Wright, G. J. & Rayner, J. C. Plasmodium falciparum erythrocyte invasion: combining function with immune evasion. PLoS Pathog 10, e1003943 (2014).
6. Saul, A. Kinetic constraints on the development of a malaria vaccine. Parasite Immunol. 9, 1-9 (1987).
7. Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2, 601 (2011).
8. Chen, L. et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog 7, e1002199 (2011).
9. Reddy, K. S. et al. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc. Natl. Acad. Sci. USA 112, 1179-1184 (2015).
10. Healer, J. et al. Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum. PLoS One 8, e72504 (2013).
11. Drew, D. R. & Beeson, J. G. PfRH5 as a candidate vaccine for Plasmodium falciparum malaria. Trends Parasitol 31, 87-88 (2015).
12. Malkin, E. M. et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73, 3677-3685 (2005).
13. Douglas, A. D. et al. A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. Cell Host Microbe 17, 130-139 (2015).
14. Singh, S. et al. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect. Immun. 74, 4573-4580 (2006).
15. Mahdi Abdel Hamid, M. et al. Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. PLoS One 6, e20547 (2011).
16. Williams, A. R. et al. Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens. PLoS Pathog 8, e1002991 (2012).
17. Bustamante, L. Y. et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine 31, 373-379 (2013).
18. Reddy, K. S. et al. Bacterially Expressed Full-Length Recombinant Plasmodium falciparum RH5 Protein Binds Erythrocytes and Elicits Potent Strain-Transcending Parasite-Neutralizing Antibodies. Infect. Immun. 82, 152-164 (2014).
19. Baum, J. et al. Reticulocyte-binding protein homologue 5-an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int. J. Parasitol. 39, 371-380 (2009).
20. Rodriguez, M., Lustigman, S., Montero, E., Oksov, Y. & Lobo, C. A. PfRH5: a novel reticulocyte-binding family homolog of plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. PLoS One 3, e3300 (2008).
21. Crosnier, C. et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480, 534-537 (2011).
22. Hayton, K. et al. Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 4, 40-51 (2008).
23. Douglas, A. D. et al. Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5. J. Immunol. 192, 245-258 (2014).
24. Mensah-Brown, H. E. et al. Analysis of Erythrocyte Invasion Mechanisms of Plasmodium falciparum Clinical Isolates Across 3 Malaria-Endemic Areas in Ghana. J. Infect. Dis. 212, 1288-1297 (2015).
25. Zenonos, Z. A. et al. Basigin is a druggable target for host-oriented antimalarial interventions. J. Exp. Med. 212, 1145-1151 (2015).
26. Tran, T. M. et al. Naturally Acquired Antibodies Specific for Plasmodium falciparum Reticulocyte-Binding Protein Homologue 5 Inhibit Parasite Growth and Predict Protection From Malaria. J. Infect. Dis. 209, 789-798 (2014).
27. Hayton, K. et al. Various PfRH5 polymorphisms can support Plasmodium falciparum invasion into the erythrocytes of owl monkeys and rats. Mol. Biochem. Parasitol. 187, 103-110 (2013).
28. Wanaguru, M., Liu, W., Hahn, B. H., Rayner, J. C. & Wright, G. J. RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 110, 20735-20740 (2013).
29. Draper, S. J. et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 14, 819-821 (2008).
30. Crosnier, C. et al. A library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins. Molecular & cellular proteomics: MCP 12, 3976-3986 (2013).
31. de Cassan, S. C. et al. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J. Immunol. 187, 2602-2616 (2011).
32. Draper, S. J. et al. Recent advances in recombinant protein-based malaria vaccines. Vaccine 33, 7433-7443 (2015).
33. Chiu, C. Y. et al. Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria. Front Microbiol. 5, 314 (2014).
34. Patel, S. D. et al. Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J. Infect. Dis. 208, 1679-1687 (2013).
35. Chen, L. et al. Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes. eLife 3, (2014).
36. Ord, R. L. et al. Targeting sialic acid dependent and independent pathways of invasion in Plasmodium falciparum. PLoS One 7, e30251 (2012).
37. Dyring, C. Optimising the Drosophila S2 Expression System for Production of Therapeutic Vaccines. BioProcessing Journal 10, 28-35 (2011).
38. Lee, J. & Blaber, M. The interaction between thermodynamic stability and buried free cysteines in regulating the functional half-life of fibroblast growth factor-1. J. Mol. Biol. 393, 113-127 (2009).
39. Brych, S. R. et al. Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation. Journal of pharmaceutical sciences 99, 764-781 (2010).
40. Wright, K. E. et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 515, 427-430 (2014).
41. Gupta, R., Jung, E. & Brunak, S. Prediction of N-glycosylation sites in human proteins http://www.cbs.dtu.dk/services/NetNGlyc/.
42. Huff, J. L., Kingsley, K. L., Miller, J. M. & Hoshizaki, D. K. Drosophila windpipe codes for a leucine-rich repeat protein expressed in the developing trachea. Mechanisms of development 111, 173-176 (2002).
43. Payne, R. O. et al. Demonstration of the Blood-Stage Controlled Human Malaria Infection Model to Assess Efficacy of the Plasmodium falciparum AMA1 Vaccine FMP2.1/AS01. J. Infect. Dis. 213, 1743-1751 (2016).
44. Miura, K. et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin. Vaccine Immunol. 16, 963-968 (2009).
45. Hodgson, S. H. et al. Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. Mol. Ther. 22, 2142-2154 (2014).
46. Gowda, D. C. & Davidson, E. A. Protein glycosylation in the malaria parasite. Parasitol Today 15, 147-152 (1999).
47. Sampath, S. et al. Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development. PLoS Pathog 9, e1003420 (2013).
48. Kapulu, M. C. et al. Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum. Sci. Rep. 5, 11193 (2015).
49. Bruder, J. T. et al. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine 28, 3201-3210 (2010).
50. Kang, Y., Calvo, P. A., Daly, T. M. & Long, C. A. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite. J. Immunol. 161, 4211-4219 (1998).
51. Stowers, A. W. et al. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 99, 339-344 (2002).
52. Boes, A. et al. Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits. Plant biotechnology journal 13, 222-234 (2015).
53. Giersing, B. et al. Posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate. Infect. Immun. 73, 3963-3970 (2005).
54. Dyring, C. Development of Pregnancy-Associated Malaria Vaccines Using the ExpreS2 Insect Cell Expression System. Bio. Processing Journal 11, 14-19 (2012).
55. Clements, D. E. et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28, 2705-2715 (2010).
56. Raposo, R. A., Thomas, B., Ridlova, G. & James, W. Proteomic-based identification of CD4-interacting proteins in human primary macrophages. PLoS One 6, e18690 (2011).
57. Ellman, G. L. Tissue sulfhydryl groups. Arch Biochem Biophys 82, 70-77 (1959).
58. Sheehy, S. H. et al. Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Mol. Ther. 19, 2269-2276 (2011).
59. Miura, K. et al. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26, 193-200 (2008).
60. Aoki, K. et al. Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila melanogaster embryo. J. Biol. Chem. 282, 9127-9142 (2007).